This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: 51/2/399    most recent HYPERTENSIONAHA.107.098988v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Engberink, M. F. Articles by Geleijnse, J. M. Search for Related Content PubMed PubMed Citation Articles by Engberink, M. F. Articles by Geleijnse, J. M. Pubmed/NCBI databases Substance via MeSH Related Collections Primary prevention

(Hypertension. 2008;51:399.)
© 2008 American Heart Association, Inc.

Original Articles

Lactotripeptides Show No Effect on Human Blood Pressure

Results From a Double-Blind Randomized Controlled Trial

Mariëlle F. Engberink; Evert G. Schouten; Frans J. Kok; Linda A.J. van Mierlo; Ingeborg A. Brouwer; Johanna M. Geleijnse

From the Division of Human Nutrition (M.F.E., E.G.S., F.J.K., I.A.B., J.M.G.), Wageningen University, Wageningen, The Netherlands; and Unilever Food & Health Research Institute (L.A.J.M.), Vlaardingen, The Netherlands.

Correspondence to Mariëlle Engberink, Wageningen University, Division of Human Nutrition, P.O. Box 8129, 6700 EV Wageningen, The Netherlands. E-mail marielle.engberink{at}wur.nl

Milk-derived peptides with ACE-inhibiting properties may have antihypertensive effects in humans. We conducted a randomized double-blind placebo-controlled trial to examine the blood pressure lowering potential of 2 ACE-inhibiting lactotripeptides, ie, Isoleucine-Proline-Proline and Valine-Proline-Proline. We included 135 Dutch subjects with elevated systolic blood pressure who were otherwise healthy and who received no current antihypertensive treatment. After a 2-week run-in period on placebo, subjects randomly received a daily dose of 200 mL dairy drink with 14 mg lactotripeptides obtained by concentrating fermented milk, enzymatic hydrolysis, or chemical synthesis, or placebo for 8 weeks, followed by a 2-week wash-out. The primary outcome was 8-week change in office systolic blood pressure. Secondary outcomes were change in diastolic blood pressure, home blood pressure, 24-hour ambulatory blood pressure, plasma ACE-activity, and plasma angiotensin II. Blood pressure at baseline was on average 142/84 mm Hg. Lactotripeptides did not significantly change systolic blood pressure (P=0.46) or diastolic blood pressure (P=0.31) compared with placebo. The mean difference (95%-CI) in systolic blood pressure response between treatment and placebo was 2.8 mm Hg (–2.6;8.2) for concentrated fermented milk lactotripeptides, –0.5 mm Hg (–6.0;5.0) for enzymatic lactotripeptides, and 1.6 mm Hg (–3.9;6.9) for synthetic lactotripeptides. Treatment neither had a significant effect on secondary outcome measures. In conclusion, the present study does not support the hypothesis of a blood pressure lowering effect of the lactotripeptides Isoleucine-Proline-Proline and Valine-Proline-Proline.

Key Words: hypertension • ACE inhibition • dairy • bioactive peptides

This article has been cited by other articles:

				L. A. van Mierlo, M. M. Koning, K. van der Zander, and R. Draijer Lactotripeptides do not lower ambulatory blood pressure in untreated whites: results from 2 controlled multicenter crossover studies Am. J. Clinical Nutrition, February 1, 2009; 89(2): 617 - 623. [Abstract] [Full Text] [PDF]

				P. M. Kris-Etherton, J. A. Grieger, K. F. Hilpert, and S. G. West Milk Products, Dietary Patterns and Blood Pressure Management J. Am. Coll. Nutr., February 1, 2009; 28(Supplement_1): 103S - 119S. [Abstract] [Full Text] [PDF]

				K. van der Zander, M. L Bots, A. A. Bak, M. M. Koning, and P. W de Leeuw Enzymatically hydrolyzed lactotripeptides do not lower blood pressure in mildly hypertensive subjects Am. J. Clinical Nutrition, December 1, 2008; 88(6): 1697 - 1702. [Abstract] [Full Text] [PDF]